Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Allogene Therapeutics

ALLO

1.9700.51% ( -0.010 )

Closed: Sep 4, 16:00:00 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

701,901 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Man Group plc
Market Beat·2 days ago, 08:48 AM
- Man Group plc acquired 701,901 shares of Allogene Therapeutics, Inc. valued at approximately $1,460,000 during the 2nd quarter. - Allogene Therapeutics reported an EPS of ($0.13) for the quarter, outperforming the consensus estimate of ($0.17) with revenue reaching $4,640,000. - Institutional investors and hedge funds collectively own 83.63% of the company's stock.
ALLO-0.51%BLK-0.34%
Allogene Therapeutics Announces Retirement of Chief Financial Officer
Tip Ranks·Sep 2 at 01:26 PM
ALLO-0.51%
Allogene Therapeutics to present at Citi Biopharma Back to School Conference
PUBT·Aug 31 at 12:30 PM
ALLO-0.51%C-0.30%
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 4.8% on Insider Selling
Market Beat·Aug 26 at 02:40 PM
ALLO-0.51%
Allogene Therapeutics Signals Progress Amid Key Risks
Tip Ranks·Aug 23 at 12:29 AM
ALLO-0.51%
Citizens Jmp Reaffirms "Market Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)
Market Beat·Aug 17 at 01:12 PM
ALLO-0.51%GS-C+0.57%
ALLO: Allogeneic CAR T platform shows strong efficacy, safety, and broad market potential across key indications
Quartr·Aug 12 at 10:53 PM
ALLO-0.51%
Allogene Therapeutics | 8-K: FY2026 Q2 Revenue: USD 4.64 M
Earnings Watch·Aug 12 at 08:31 PM
ALLO-0.51%
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Unusual Whales·Aug 12 at 08:30 PM
ALLO-0.51%
ALLO: Q2 2026 net loss narrowed to $42.7M; cash runway extends into 2029 as key trials progress
Quartr·Aug 12 at 08:26 PM
ALLO-0.51%
Allogene Q2 FY26 net loss narrows to $42.68 million; revenue rises to $4.64 million
PUBT·Aug 12 at 08:14 PM
ALLO-0.51%